METHAMPHETAMINE

Methamphetamine is a Schedule II stimulant with limited medical use (ADHD, obesity) under the brand Desoxyn. Epidemiological data show rising global use with cardiovascular disease as the leading cause of mortality after overdose. Chronic use is causally linked to pulmonary arterial hypertension, cardiomyopathy, hemorrhagic stroke, and accelerated neurodegeneration. Evidence supports an association with early-onset Parkinson's disease, though direct dopaminergic neuron degeneration has not been conclusively demonstrated. No approved pharmacotherapy exists for methamphetamine use disorder; treatment relies on behavioral interventions. The evidence base for long-term neurological harm is strong, while mechanisms underlying pulmonary hypertension remain poorly understood.